Elsevier

Clinical Therapeutics

Volume 32, Issue 4, April 2010, Pages 717-728
Clinical Therapeutics

A health-economic evaluation of disease-modifying drugs for the treatment of relapsing-remitting multiple sclerosis from the German societal perspective

https://doi.org/10.1016/j.clinthera.2010.03.019Get rights and content

Abstract

Objective: This analysis compared the cost-effectiveness of interferon beta-1a (IFNβ-1a) 44 μg SC with that of other available first-line treatments for relapsing-remitting multiple sclerosis (RRMS) from the German societal perspective in 2008.

Methods: A decision-analytic model was used to estimate the cost-effectiveness of IFNβ-1a 44 μg SC given 3 times weekly compared with that of IFNβ-la 30 μg IM given once weekly, IFNβ-1b 8 mIU given every other day, and glatiramer acetate 20 mg SC given once daily. Data sources included the published literature, clinical trials, German price/tariff lists, and national population statistics. The time horizon of the model was 4 years, which was the maximum duration of follow-up in published clinical trials.

Results: The cost-effectiveness (cost per relapse avoided) of IFNβ-la 44 μg SC compared with no active treatment was €51,250, which compared favorably with that of IFNβ-la 30 μg IM (€133,770), glatiramer acetate (€71,416), and IFNβ-1b (€54,475). When the cost of disease progression was excluded, the cost per relapse avoided remained favorable for IFNβ-1a 44 μg SC (€54,292) compared with the other options (€143,186, €72,809, and €56,816, respectively). Indirect comparison of each available treatment option with the next best alternative indicated that the incremental cost-effectiveness of IFNβ-la 44 μg SC (€23,449) was consistent with accepted thresholds. Sensitivity analyses in which the discount rate, frequency of relapse and disease progression, costs of relapse and disease progression, and adherence were varied did not affect the relative outcomes.

Conclusion: In this analysis from the German societal perspective, IFNβ-la 44 μg SC had favorable overall cost-effectiveness versus no active treatment compared with other available disease-modifying drugs for the treatment of RRMS.

References (44)

  • BG Weinshenker

    The natural history of multiple sclerosis

    Neurol Clin

    (1995)
  • Leitlinien der DGN 2008. Diagnostik and Therapie der Multiplen...
  • SL Hauser

    Multiple sclerosis and other demyelinating diseases

  • JH Noseworthy et al.

    Multiple sclerosis

    N Engl J Med

    (2000)
  • BG Weinshenker et al.

    The natural history of multiple sclerosis: A geographically-based study. 2. Predictive value of the early clinical course

    Brain

    (1989)
  • MJ Rieumont et al.

    Neuroimaging evaluation in multiple sclerosis

    Am Fam Physician

    (1993)
  • PL Hibberd

    The use and misuse of statistics for epidemiological studies of multiple sclerosis

    Ann Neurol

    (1994)
  • W Clark

    Therapeutic advances: Beta-interferon for multiple sclerosis

    J Clin Pharm Ther

    (1996)
  • DE Goodkin et al.

    Exacerbation rates and adherence to disease type in a prospectively followed-up population with multiple sclerosis. Implications for clinical trials

    Arch Neurol

    (1989)
  • DJ Weatherall et al.
  • RA Rudick et al.

    Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis

    Arch Neurol

    (1992)
  • Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis [published correction appears in Lancet. 1999;353:678]

    Lancet

    (1998)
  • Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial

    Neurology

    (1993)
  • Placebo-controlled multicenter randomised trial of interferon beta-1b in treatment of sec ondary progressive multiple sclerosis

    Lancet

    (1998)
  • M Catanzaro et al.

    Economic status of families living with multiple sclerosis

    Int J Rehabil Res

    (1992)
  • G Kobelt et al.

    Costs and quality of life of multiple sclerosis in Germany

    Eur J Health Econ

    (2006)
  • FD Weinfeld et al.

    The National Multiple Sclerosis Survey. Background and economic impact

    Ann N Y Acad Sci

    (1984)
  • BG Weinshenker et al.

    Meta-analysis of the placebo-treated groups in clinical trials of progressive MS

    Neurology

    (1996)
  • N LaRocca et al.

    The role of disease and demographic factors in the employment of patients with multiple sclerosis

    Arch Neurol

    (1982)
  • HJ Bauer et al.

    Prognostic criteria in multiple sclerosis

    Ann N Y Acad Sci

    (1965)
  • M Grønning et al.

    Multivariate analyses of factors associated with unemployment in people with multiple sclerosis

    J Neurol Neurosurg Psychiatry

    (1990)
  • View full text